Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Roxadustat · FG-4592, AZD9941

Small molecule · Inhibitor of hypoxia-inducible factor prolyl hydroxylase (EGLN1) · developed by Kyntra Bio

Phase 4 Most advanced trial (none active)
KYNB Developer
3 Registered trials

What is Roxadustat?

Roxadustat is an orally bioavailable hypoxia-inducible factor prolyl hydroxylase inhibitor. It blocks degradation of HIF transcription factors, increasing endogenous erythropoietin production, reducing hepcidin and improving iron availability. It is studied in anemia, myelodysplastic syndrome and anemia in chronic kidney disease patients on dialysis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FG-4592, AZD9941, ASP-1517
Drug type
Small molecule
Targets
hypoxia-inducible factor prolyl hydroxylase (EGLN1)
Mechanism
Inhibitor of hypoxia-inducible factor prolyl hydroxylase (EGLN1)
Pathways
HIF signaling, erythropoietin production, erythropoiesis, iron metabolism
Therapy area
Hematology, Renal & urology
Developer
Kyntra Bio (KYNB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 4
UNII
X3O30D9YMX

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04059913 Phase 4 CKD Anemia in Dialysis Participants Completed KYNB
NCT03303066 Phase 2/3 Anemia Completed KYNB
NCT02952040 Phase 1 Healthy Subjects Completed KYNB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AnemiaCKD Anemia in Dialysis ParticipantsHealthy SubjectsMyelodysplastic Syndrome

More from Kyntra Bio

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KYNB page.

Follow KYNB, the company behind Roxadustat

See KYNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KYNB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.